CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
Go back to CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer| CEL-SCI CORPORATION (NYSE: CVM) | Delayed: 1.66 +0.17 (11.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.49 | 52 Week High | $0.66 | |||
| Open | $1.53 | 52 Week Low | $0.20 | |||
| Day High | $1.70 | P/E | N/A | |||
| Day Low | $1.51 | EPS | $-0.34 | |||
| Volume | 270,346 | |||||
